51P - Pathological complete response (pCR) is not a good marker for inflammatory breast cancer (IBC) patients to predict improved long-term survival after...

Date 07 May 2015
Event IMPAKT 2015
Session Welcome reception and Poster Walk
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer
Translational Research
Presenter Fei Fei
Citation Annals of Oncology (2015) 26 (suppl_3): 15-24. 10.1093/annonc/mdv117
Authors F. Fei, L. Tang, G. Di
  • Breast Surgery Department, Shanghai Cancer Center Fudan University, 200032 - Shanghai/CN

Abstract

Body

Background: Not all breast cancer patients with pathological complete response (pCR) after neoadjuvant chemotherapy (NT) have a favorable outcome. Relapse can be observed during the follow-up. We aim to identify predictive factors for relapse after pCR in inflammatory breast cancers (IBC) subgroup and evaluate pCR as an endpoint of long term survival after NT in these patients.

Methods: 337 IBC patients received taxane-based NT from 2008 to 2013, and 58 patients achieved a pCR, defined as no evidence of invasive carcinoma in both breast and axillary lymph node at surgery. Among 35 patients with HER2-positive tumours, 27 received trastuzumab. Cox regression analyses were performed to identify predictors of recurrence. Kaplan Meier curves were used for relapse free survival (RFS) and overall survival (OS).

Results: Median follow-up was 42.5 months. 9 IBC patients with pCR developed distant relapses and no local regional recurrences occurred. Triple Negative subtype was the only predictor for RFS (HR 2.77, p < 0.05). Compared with non-pCR patients, IBC patients didn't obtain improved 5-year RFS even after achieving pCR. (HR: 0.88, P = 0.78). There were no significant differences in 5- year OS between IBC patients with and without pCR. (HR: 0.72, p = 0.63).

Conclusion: Triple Negative subtype is the only predictor for relapse after pCR in IBC patients. pCR is not a good marker for IBC patients to predict improved long term survival after NT.

Disclosure: All authors have declared no conflicts of interest.